Randomized trial to compare smoking cessation rates of snus, with and without smokeless tobacco health-related information, and a nicotine lozenge

Nicotine and Tobacco Research

Volumn 21, Issue 1, 2019, Pages 88-94

  Nelson, Paul R ^a   Chen, Peter ^a   Battista, Deena R ^b   Pillitteri, Janine L ^c   Shiffman, Saul ^b  

^a RAI Services Company   (United States)

^b Pinney Assoct   (United States)

^c PinneyAssociates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE; NICOTINE GUM;

ADULT; ADVERSE EVENT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FOLLOW UP; HUMAN; LOZENGE; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MOTIVATION; MOUTH LESION; MULTICENTER STUDY; NAUSEA; NICOTINE REPLACEMENT THERAPY; PHARYNGITIS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; SINUSITIS; SMOKING CESSATION; SNUS; TOBACCO DEPENDENCE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; CLASSIFICATION; CLINICAL TRIAL; COUNSELING; EPIDEMIOLOGY; LONGITUDINAL STUDY; MIDDLE AGED; PROCEDURES; PSYCHOLOGY; SMOKELESS TOBACCO; SMOKING; THERAPY; YOUNG ADULT;

ADULT; AGED; COUNSELING; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NICOTINE; SMOKERS; SMOKING; SMOKING CESSATION; TOBACCO USE CESSATION DEVICES; TOBACCO, SMOKELESS; YOUNG ADULT;

EID: 85058914660     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/nty011     Document Type: Article

References (37)

1. Gitchell JG, Shiffman S, Sembower MA. Trends in serious quit attempts in the United States, 2009-14. Addiction. 2017;112(5):897-900.
2. Lavinghouze SR, Malarcher A, Jama A, Neff L, Debrot K, Whalen L. Trends in quit attempts among adult cigarette smokers - United States, 2001-2013. MMWR Morb Mortal Wkly Rep. 2015;64(40):1129-1135.
3. U.S. Food and Drug Administration. Now available without a prescription. Information for Consumers. 2016. https://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143547.htm. Accessed June 30, 2017.
4. Babb S, Malarcher A, Schauer G, Asman K, Jamal A. Quitting smoking among adults - United States, 2000-2015. MMWR Morb Mortal Wkly Rep. 2017;65(52):1457-1464.
5. Mooney ME, Leventhal AM, Hatsukami DK. Attitudes and knowledge about nicotine and nicotine replacement therapy. Nicotine Tob Res. 2006;8(3):435-446.
6. Shiffman S, Ferguson SG, Rohay J, Gitchell JG. Perceived safety and efficacy of nicotine replacement therapies among US smokers and ex-smokers: relationship with use and compliance. Addiction. 2008;103(8):1371-1378.
7. Lee PN, Hamling J. Systematic review of the relation between smokeless tobacco and cancer in Europe and North America. BMC Med. 2009;7:36.
8. Nutt DJ, Phillips LD, Balfour D, et al. Estimating the harms of nicotine-containing products using the MCDA approach. Eur Addict Res. 2014;20(5):218-225.
9. Borgerding MF, Bodnar JA, Curtin GM, Swauger JE. The chemical composition of smokeless tobacco: a survey of products sold in the United States in 2006 and 2007. Regul Toxicol Pharmacol. 2012;64(3):367-387.
10. Lee PN. Epidemiological evidence relating snus to health-an updated review based on recent publications. Harm Reduct J. 2013;10:36.
11. Levy DT, Mumford EA, Cummings KM, et al. The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts. Cancer Epidemiol Biomarkers Prev. 2004;13(12):2035-2042.
12. Fagerstrom K, Rutqvist LE, Hughes JR. Snus as a smoking cessation aid: a randomized placebo-controlled trial. Nicotine Tob Res. 2012;14(3):306-312.
13. Joksić G, Spasojević-Tišma V, Antić R, Nilsson R, Rutqvist LE. Randomized, placebo-controlled, double-blind trial of Swedish snus for smoking reduction and cessation. Harm Reduct J. 2011;8:25.
14. Tønnesen P, Mikkelsen K, Bremann L. Smoking cessation with smokeless tobacco and group therapy: an open, randomized, controlled trial. Nicotine Tob Res. 2008;10(8):1365-1372.
15. Bobak A, Shiffman S, Gitchell JG, Bery J, Ferguson SG. Perceived safety of nicotine and the use of nicotine replacement products among current smokers in Great Britain: results from two national surveys. J Smoking Cessation. 2010;5(2):115-122.
16. Ferguson SG, Gitchell JG, Shiffman S, Sembower MA, Rohay JM, Allen J. Providing accurate safety information may increase a smoker's willingness to use nicotine replacement therapy as part of a quit attempt. Addict Behav. 2011;36(7):713-716.
17. Fong G, Elton-Marshall T, Driezen P, et al. 2016. Adult perceptions of the harmfulness of tobacco products: Descriptive findings from wave 1 of the PATH study, 2013-14. Poster session presented at the Society for Research on Nicotine and Tobacco Annual Meeting; 2016 March 2-5; Chicago, IL.
18. Kaufman AR, Mays D, Koblitz AR, Portnoy DB. Judgments, awareness, and the use of snus among adults in the United States. Nicotine Tob Res. 2014;16(10):1404-1408.
19. Kiviniemi MT, Kozlowski LT. Deficiencies in public understanding about tobacco harm reduction: results from a United States national survey. Harm Reduct J. 2015;12:21.
20. Regan AK, Dube SR, Arrazola R. Smokeless and flavored tobacco products in the U.S.: 2009 Styles survey results. Am J Prev Med. 2012;42(1):29-36.
21. Shiffman S, Dresler CM, Hajek P, Gilburt SJ, Targett DA, Strahs KR. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med. 2002;162(11):1267-1276.
22. Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res. 2003;5(1):13-25.
23. SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine Tob Res. 2002;4(2):149-159.
24. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The fager-ström test for nicotine dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86(9):1119-1127.
25. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD000146.
26. Shiffman S, Rolf CN, Hellebusch SJ, et al. Real-world efficacy of prescription and over-the-counter nicotine replacement therapy. Addiction. 2002;97(5):505-516.
27. Hughes JR, Shiffman S, Callas P, Zhang J. A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control. 2003;12(1):21-27.
28. Leischow SJ, Muramoto ML, Cook GN, Merikle EP, Castellini SM, Otte PS. OTC nicotine patch: effectiveness alone and with brief physician intervention. Am J Health Behav. 1999;23(1):61-69.
29. Leischow SJ, Ranger-Moore J, Muramoto ML, Matthews E. Effectiveness of the nicotine inhaler for smoking cessation in an OTC setting. Am J Health Behav. 2004;28(4):291-301.
30. Choi JH, Dresler CM, Norton MR, Strahs KR. Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob Res. 2003;5(5):635-644.
31. Cobb CO, Weaver MF, Eissenberg T. Evaluating the acute effects of oral, non-combustible potential reduced exposure products marketed to smokers. Tob Control. 2010;19(5):367-373.
32. Baker TB, Piper ME, McCarthy DE, et al. Time to first cigarette in the morning as an index of ability to quit smoking: Implications for nicotine dependence. Nicotine Tob Res. 2007;9(suppl 4):S555-S570.
33. Glover ED, Sachs DPL, Stitzer ML, et al. Smoking cessation in highly dependent smokers with 4 mg nicotine polacrilex. Am J Health Behav. 1996;20(5):319-332.
34. Shiffman S. Use of more nicotine lozenges leads to better success in quitting smoking. Addiction. 2007;102(5):809-814.
35. Kozlowski LT, Sweanor DT. 'Not harmless' messages without comparisons disserve consumers, potential consumers, and public health approaches to tobacco/nicotine products. Addict Behav. 2018;76:390-391.
36. Kozlowski LT, Sweanor D. Withholding differential risk information on legal consumer nicotine/tobacco products: The public health ethics of health information quarantines. Int J Drug Policy. 2016;32:17-23.
37. FLESCH R. A new readability yardstick. J Appl Psychol. 1948;32(3): 221-233.